YNIOS PHARMA is a pre-clinical biotech company developing an innovative therapeutic platform for patients with life-threatening critical illnesses, starting with sepsis and septic shock — among the leading causes of death in intensive care units (ICUs).

Our lead compound, TA64, targets the fundamental pathophysiological mechanisms driving multi-organ failure, including dysregulated inflammation, endothelial dysfunction, microcirculatory failure, and immune exhaustion.

Beyond septic shock, we aim to extend our platform to other ICU conditions sharing similar biological pathways, such as acute respiratory failure syndromes (ARDS, severe COVID-19, influenza), systemic inflammatory states (SIRS, early-stage sepsis), and trauma- or burn-related critical illness.

By addressing these shared mechanisms, TA64 offers the potential for a unified, mechanism-based therapy across a spectrum of high-mortality ICU indications.